Edition:
United States

Aveo Pharmaceuticals Inc (AVEO.OQ)

AVEO.OQ on NASDAQ Stock Exchange Global Select Market

0.84USD
22 Mar 2017
Change (% chg)

-- (--)
Prev Close
$0.84
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
45,494
52-wk High
$1.14
52-wk Low
$0.54

Latest Key Developments (Source: Significant Developments)

Aveo Pharmaceuticals says doubts ability to continue as a going concern - SEC filing
Wednesday, 22 Mar 2017 04:35pm EDT 

Aveo Pharmaceuticals Inc : Aveo Pharmaceuticals says have identified conditions and events that raise substantial doubt about ability to continue as a going concern - SEC filing . Aveo Pharmaceuticals says "continue as a going concern, we must secure additional capital to provide us with additional liquidity" . Aveo Pharma - believe about $23.3 million in existing cash,cash equivalents, securities at Dec. 31, 2016, could allow to fund planned operations into Q4 2017 .Aveo Pharmaceuticals Inc says additional funds will be needed to extend planned operations into 2018.  Full Article

Aveo reports full year 2016 financial results
Wednesday, 22 Mar 2017 04:05pm EDT 

Aveo Pharmaceuticals Inc - : Aveo reports full year 2016 financial results and provides business update . Aveo Pharmaceuticals - $23.3 million in cash,cash equivalents,marketable securities as of Dec 31, 2016 could allow co to fund planned operations into q4 2017 .Qtrly loss per share $0.07.  Full Article

Aveo announces first patient dosed in phase 1/2 tinivo trial
Wednesday, 22 Mar 2017 07:00am EDT 

Aveo Pharmaceuticals Inc : Aveo announces first patient dosed in phase 1/2 tinivo trial of tivozanib and opdivo (nivolumab) in advanced RCC . Aveo Pharmaceuticals Inc - phase 1 trial will evaluate safety of tivozanib in combination with nivolumab at escalating doses of tivozanib .Aveo Pharmaceuticals Inc - look forward to initial results from phase 1 portion of tinivo trial in first half of 2017.  Full Article

Aveo reports clinical and regulatory updates for tivozanib
Thursday, 9 Feb 2017 04:05pm EST 

Aveo Pharmaceuticals Inc : Aveo announces clinical and regulatory updates for tivozanib . Aveo Pharmaceuticals Inc- phase 1/2 tinivo trial sites scheduled to open for enrollment in early march . Aveo Pharmaceuticals Inc- partner Eusa Pharma receives day 180 list of outstanding issues from EMA, oral explanation expected in 2q 2017 . Aveo Pharmaceuticals Inc- pivotal tivo-3 trial enrollment proceeding substantially ahead of schedule; enrollment completion expected in June .Aveo Pharmaceuticals Inc- initial results from opdivo(reg) combination tinivo study expected in RCC in first half of 2017.  Full Article

Aveo Oncology Q3 loss per share $0.07
Friday, 4 Nov 2016 07:00am EDT 

Aveo Pharmaceuticals Inc : Says believe that $30.8 million in cash resources could allow to fund planned operations into Q4 of 2017 . Aveo Pharma -expect approval decision in first-line renal cell cancer in europe, initial results from opdivo(reg) combination tinivo study in h1 2017 . Sees top-line data from U.S.-registration-directed phase 3 tivo-3 study in renal cell cancer in q1 of 2018 . Aveo oncology reports third quarter 2016 financial results and provides business update .Q3 loss per share $0.07.  Full Article

Aveo initiates evaluation of Tivozanib in combination with Bristol-Myers Squibb's opdivo in advanced renal cell carcinoma
Monday, 15 Aug 2016 07:00am EDT 

Aveo : Initiates Evaluation Of Tivozanib In Combination With Bristol Myers Squibb's Opdivo® (nivolumab) in advanced renal cell carcinoma .Phase 1/2 tinivo trial to commence at institut gustave roussy in paris.  Full Article

Aveo Oncology Q2 loss per share $0.13
Thursday, 4 Aug 2016 07:35am EDT 

Aveo Pharmaceuticals Inc : Aveo oncology reports second quarter 2016 financial results and provides business update . Q2 loss per share $0.13 Further company coverage: [AVEO.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Aveo Pharmaceuticals says sale of 37.1 mln shares by stockholders
Wednesday, 15 Jun 2016 05:12pm EDT 

Aveo Pharmaceuticals Inc :Announces sale of 37.1 million shares of common stock by selling stockholders - sec filing.  Full Article

Aveo Pharmaceuticals announces dosing of first patient in Phase 3 tivo-3 study of tivozanib in renal cell carcinoma
Thursday, 26 May 2016 07:00am EDT 

Aveo Pharmaceuticals Inc : Announces dosing of first patient in pivotal Phase 3 tivo 3 study of tivozanib in renal cell carcinoma .Top line readout of study is currently projected for Q1 of 2018.  Full Article

Aveo Pharmaceuticals announces closing of private placement and amended term loan
Wednesday, 18 May 2016 07:00am EDT 

Aveo Pharmaceuticals Inc : Announces closing of private placement and amended term loan to fund pivotal Tivo 3 trial and combination PD-1 trial of tivozanib in renal cell cancer . Entered into an amendment to its 2010 loan and security agreement with Hercules Capital Inc . Pursuant to loan amendment, company borrowed an additional $5.0 million from Hercules . If specified conditions are met, Aveo may borrow an additional tranche of $5.0 million from Hercules in first half of 2017 .If specified conditions are met, repayment of principal on Aveo's loans may be deferred to begin in 2018.  Full Article

More From Around the Web

BRIEF-Aveo Pharmaceuticals says doubts ability to continue as a going concern - SEC filing

* Aveo Pharmaceuticals says have identified conditions and events that raise substantial doubt about ability to continue as a going concern - SEC filing